These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 25249652

  • 21. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
    Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J.
    Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
    [Abstract] [Full Text] [Related]

  • 22. Tolerability and safety of the new anti-obesity medications.
    Hainer V, Aldhoon-Hainerová I.
    Drug Saf; 2014 Sep; 37(9):693-702. PubMed ID: 25096956
    [Abstract] [Full Text] [Related]

  • 23. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
    Kelly EM, Tungol AA, Wesolowicz LA.
    J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010
    [Abstract] [Full Text] [Related]

  • 24. Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes.
    Stenlöf K, Rössner S, Vercruysse F, Kumar A, Fitchet M, Sjöström L, OBDM-003 Study Group.
    Diabetes Obes Metab; 2007 May; 9(3):360-8. PubMed ID: 17391164
    [Abstract] [Full Text] [Related]

  • 25. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management.
    Garvey WT.
    Expert Opin Drug Saf; 2013 Sep; 12(5):741-56. PubMed ID: 23738843
    [Abstract] [Full Text] [Related]

  • 26. The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension.
    Tremblay A, Chaput JP, Bérubé-Parent S, Prud'homme D, Leblanc C, Alméras N, Després JP.
    Eur J Clin Pharmacol; 2007 Feb; 63(2):123-34. PubMed ID: 17200837
    [Abstract] [Full Text] [Related]

  • 27. Combination phentermine and topiramate for weight maintenance: the first Australian experience.
    Neoh SL, Sumithran P, Haywood CJ, Houlihan CA, Lee FT, Proietto J.
    Med J Aust; 2014 Aug 18; 201(4):224-6. PubMed ID: 25164851
    [Abstract] [Full Text] [Related]

  • 28. Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1BRx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes.
    Digenio A, Pham NC, Watts LM, Morgan ES, Jung SW, Baker BF, Geary RS, Bhanot S.
    Diabetes Care; 2018 Apr 18; 41(4):807-814. PubMed ID: 29439147
    [Abstract] [Full Text] [Related]

  • 29. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A.
    Clin Ther; 2004 Sep 18; 26(9):1427-35. PubMed ID: 15531005
    [Abstract] [Full Text] [Related]

  • 30. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.
    Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, Klassen P, Fujioka K, COR-Diabetes Study Group.
    Diabetes Care; 2013 Dec 18; 36(12):4022-9. PubMed ID: 24144653
    [Abstract] [Full Text] [Related]

  • 31. Combination treatment to CONQUER obesity?
    Shah K, Villareal DT.
    Lancet; 2011 Apr 16; 377(9774):1295-7. PubMed ID: 21497686
    [No Abstract] [Full Text] [Related]

  • 32. Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
    Elkind-Hirsch KE, Chappell N, Seidemann E, Storment J, Bellanger D.
    J Clin Endocrinol Metab; 2021 Sep 27; 106(10):3019-3033. PubMed ID: 34097062
    [Abstract] [Full Text] [Related]

  • 33. Phentermine and topiramate extended release (Qsymia™): first global approval.
    Cameron F, Whiteside G, McKeage K.
    Drugs; 2012 Oct 22; 72(15):2033-42. PubMed ID: 23039320
    [Abstract] [Full Text] [Related]

  • 34. A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa.
    Safer DL, Adler S, Dalai SS, Bentley JP, Toyama H, Pajarito S, Najarian T.
    Int J Eat Disord; 2020 Feb 22; 53(2):266-277. PubMed ID: 31721257
    [Abstract] [Full Text] [Related]

  • 35. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E, COR-I Study Group.
    Lancet; 2010 Aug 21; 376(9741):595-605. PubMed ID: 20673995
    [Abstract] [Full Text] [Related]

  • 36. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects.
    Astrup A, Caterson I, Zelissen P, Guy-Grand B, Carruba M, Levy B, Sun X, Fitchet M.
    Obes Res; 2004 Oct 21; 12(10):1658-69. PubMed ID: 15536230
    [Abstract] [Full Text] [Related]

  • 37. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
    Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S.
    JAMA; 2016 Jun 14; 315(22):2424-34. PubMed ID: 27299618
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study.
    Silberstein SD, Hulihan J, Karim MR, Wu SC, Jordan D, Karvois D, Kamin M.
    Clin Ther; 2006 Jul 14; 28(7):1002-11. PubMed ID: 16990078
    [Abstract] [Full Text] [Related]

  • 39. Cardiovascular Safety During and After Use of Phentermine and Topiramate.
    Ritchey ME, Harding A, Hunter S, Peterson C, Sager PT, Kowey PR, Nguyen L, Thomas S, Cainzos-Achirica M, Rothman KJ, Andrews EB, Anthony MS.
    J Clin Endocrinol Metab; 2019 Feb 01; 104(2):513-522. PubMed ID: 30247575
    [Abstract] [Full Text] [Related]

  • 40. Study protocol and rationale for a randomized double-blinded crossover trial of phentermine-topiramate ER versus placebo to treat binge eating disorder and bulimia nervosa.
    Dalai SS, Adler S, Najarian T, Safer DL.
    Contemp Clin Trials; 2018 Jan 01; 64():173-178. PubMed ID: 29038069
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.